GDNF and Parkinson disease: This technology was successfully tested in rodent models of PD using a chimeric monoclonal antibody against the mouse transferrin receptor fusion protein (cTfRmAb-GDNF) [17], suggesting that delivery of GDNF fusion protein may be a viable treatment option.